ORIGINAL ARTICLESafety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies
Under a Creative Commons license
open access
KEYWORDS
clinical research/practice
complement biology
donors and donation: deceased
immunosuppressant-fusion proteins and monoclonal antibodies
kidney transplantation/nephrology
rejection: antibody-mediated (ABMR)
sensitization
Abbreviations
AMR
antibody-mediated rejection
BFXM
B cell flow crossmatch
CDC
complement-dependent cytotoxicity
CI
confidence interval
DGF
delayed graft function
DSA
donor-specific antibody
HLA
human leukocyte antigen
IdeS
IgG-degrading endopeptidase derived from Streptococcus pyogenes
IgG
immunoglobulin G
IVIg
intravenous immunoglobulin
mcs
mean channel shift
MFI
mean fluorescence intensity
MMF
mycophenolate mofetil
PP
plasmapheresis
SAE
serious adverse event
SCr
serum creatinine
SD
standard deviation
TAC
tacrolimus
TEAE
treatment-emergent adverse event
TFXM
T cell flow crossmatch
Cited by (0)
- *
All C10-002 Study Investigators are listed in the Supporting Information.
Copyright © 2019 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.